Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions

In the POLARIX trial, pola‐R‐CHP demonstrated improved progression‐free survival (PFS) compared to R‐CHOP in untreated intermediate‐ to high‐risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of efficacy, safety, and cost. Of 174 respondent...

Descripción completa

Detalles Bibliográficos
Autores principales: Major, Ajay, Cliff, Edward R. Scheffer, Ermann, Daniel A., Durani, Urshila, Russler‐Germain, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422021/
https://www.ncbi.nlm.nih.gov/pubmed/36051026
http://dx.doi.org/10.1002/jha2.505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422021/
https://www.ncbi.nlm.nih.gov/pubmed/36051026
http://dx.doi.org/10.1002/jha2.505

Ejemplares similares